13 January 2020 - Medicines which can be used to treat prostate cancer, primary progressive multiple sclerosis, a rare form of lymphoma and migraine have today been accepted by the Scottish Medicines Consortium for use by NHSScotland.

Abiraterone acetate (Zytiga), used in combination with androgen deprivation therapy, was accepted for the treatment of newly diagnosed metastatic prostate cancer. The medicine was considered through SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.

Also accepted through PACE was ocrelizumab (Ocrevus) for early primary progressive multiple sclerosis.

Read SMC press release